摘要
胰高血糖素样肽-1(GLP-1)是一种由肠道L细胞分泌,在碳水化合物的刺激下促进胰岛素的分泌进而降低血糖的一种物质。胰高血糖素样肽-1受体激动剂(GLP-1RA)是通过刺激人体内源性GLP-1的生成而产生降糖作用,因其良好的降糖效果及其对于大、小血管的保护作用而广受临床医生及科研专家的关注。本文通过检索文献对其心血管获益、减重方面进行综述,并对目前已在我国上市并在临床上取得良好应用的几种GLP-1RA进行简要介绍。
Glucagon-like peptide-1 is a substance which is secreted by intestinal L cell and stimulated by carbohydrates to secrete enough insulin to reduce blood glucose. Glucagon-like peptide 1 receptor agonist ( GLP-1RAs) has a hypoglycemic effect by stimulating the production of endogenous GLP-1 in human body. It is widely concerned by clinicians and scientific research experts because of its good hypoglycemic effect and its protective effect on vessels. Through literature search,this paper firstly reviews the cardiovascular benefits, weight loss and other aspects, and briefly introduces several GLP-1RAs which have been listed in China and have been applied in clinical practice.
作者
张宁倩
王清
Ning-qian;WANG Qing(Department of Endocrinology,China Japan Union Hospital of Jilin University,Changchun 133000,China)
出处
《实用药物与临床》
CAS
2019年第7期677-679,共3页
Practical Pharmacy and Clinical Remedies
关键词
胰高血糖素样肽-1受体激动剂
2型糖尿病
减重
血管获益
肾功能
Glucagon-like peptide-1 agonists
Type 2 diabetes mellitus
Weight loss
Cardiovascular benefits
Renal function
